Shin Nippon Biomedical Laboratories News and Activities
Presence
Shin Nippon Biomedical Laboratories provides drug development and support services for biotechnology and pharmaceutical companies. Its main services include nonclinical testing, clinical trial support, and laboratory research for healthcare customers.
Shin Nippon Biomedical Laboratories products and services overview:
- Nonclinical testing
- Clinical trial support
- Laboratory research
- Drug development services
- Bioanalytical services
Revenue: ~$245 million
Employees: 1,600
Headquarters: Kagoshima, Japan
Shin Nippon Biomedical Laboratories is one of the...
Shin Nippon Biomedical Laboratories is a company listed under the stock ticker 2395 (JP).
Executives
View the org chart displaying its 20 main executives
Most searched biographies at Shin Nippon Biomedical Laboratories
- Ryoichi Nagata, Chairman of the Board, Chief Executive Officer, Ch...
- Yoshikazu Shigehisa, Director
- Takashi Yamashita, Non-Executive Independent Director
Create your alert
to follow the executive moves at Shin Nippon Biomedical Laboratories.
Biotechnology
Shin Nippon Biomedical Laboratories has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Ona Therapeutics has just announced a $87 Million fundraising (posted on June 5 2026).
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
Popular contacts in Biotechnology
News
Press releases by Shin Nippon Biomedical Laboratories
- Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Wave Life Sciences
- Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency - Wave Life Sciences
- Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease - Wave Life Sciences
- Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping - Wave Life Sciences
- Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares - Wave Life Sciences
- We released materials for presentation on nasal administration basic technology briefing session - SNBL
- Financial News Archive-SNBL
- View more press releases Close
Social media about Shin Nippon Biomedical Laboratories
- Shin Nippon Biomedical Laboratories on Wikipedia, Google News & Yahoo Finance
- Shin Nippon Biomedical Laboratories on LinkedIn, X (Twitter) & YouTube
